FATI-01
- Disease/Condition
- Infections and Infestations
- Primary sponsor
- French National Agency of Research On Aids and Viral Hepatitis (ANRS); Klinikum der Universität München, Prof. Dr. med. Burkhard Göke
- Funder
- European and Developing Countries Clinical Trials Partnership (EDCTP); German Federal Ministry of Education and Research; French National Agency of Research On Aids and Viral Hepatitis (ANRS); EDCTP
- Location
- Pan Africa
- Phase
- Phase 2
- Start date
- Jan 07, 2013
- End date
- Jan 01, 1900
A prospective, multicenter, open, randomized Phase 2a trial to confirm a sustained virological suppression defined as HIV-RNA <50 copies/ml of 3 different doses of Fozivudine in context to a standard Zidovudine based antiretroviral therapy regimen after 24 weeks of treatment in ART naïve, non subtype B HIV-1 infected individuals from Tanzania and Ivory Coast.The primary objective is to confirm a sustained virological suppression (HIV RNA <50 copies/ml) after 24 weeks of treatment.
- Registry
- Pan Africa Clinical Trials Registry
- Trial ID
- PACTR201205000384379
- Type
- Non-Device Trial
Access comprehensive clinical trial information for PACTR201205000384379 through Pure Global AI's free database. This Phase 2 trial is sponsored by French National Agency of Research On Aids and Viral Hepatitis (ANRS); Klinikum der Universität München, Prof. Dr. med. Burkhard Göke and is currently Completed. The study focuses on Infections and Infestations.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Pan Africa Clinical Trials Registry data, helping medical device and pharmaceutical companies navigate clinical research efficiently.